Compounds > azacitidine

azacitidine and panobinostat

azacitidine has been researched along with panobinostat in 19 studies

Research

Studies (19)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's2 (10.53)29.6817
2010's16 (84.21)24.3611
2020's1 (5.26)2.80

Authors

AuthorsStudies
Chiba, DE; Dos Santos, JL; Lopes, JR1
Atadja, P; Bhalla, K; Chen, J; Eaton, K; Fernandez, P; Fiskus, W; Herger, B; Joshi, R; Kolhe, R; Lee, P; Mandawat, A; Peiper, S; Rao, R; Wang, Y; Yang, Y1
Atadja, P; Balusu, R; Bhalla, KN; Buckley, K; Chen, J; Fiskus, W; Joshi, A; Joshi, R; Koul, S; Mandawat, A; Rao, R; Upadhyay, S; Wang, Y; Yang, Y1
Borden, EC; Cheriyath, V; Luszczek, W; Mekhail, TM1
Amengual, J; Bhagat, G; Kalac, M; Leshchenko, VV; Marchi, E; O'Connor, OA; Parekh, S; Scotto, L; Seshan, VE; Temkin, AM; Tycko, B; Ulahannan, N1
Atadja, P; Feng, X; Ganapathy, A; Kumar Mishra, M; Morris, D; Qiao Shi, Z; Riabowol, K; Thakur, S1
Goodson, H; Helquist, P; Huegel, KL; Hulett, TW; Vaughan, KT; Wehrmann, ZT; Wiest, O1
Atadja, P; Banks, KM; Bergsagel, PL; Chesi, M; Doyle, MA; Ellul, J; Faulkner, D; Johnstone, RW; Lefebure, M; Matthews, GM; Shortt, J; Vidacs, E1
Govindaraj, C; Plebanski, M; Spencer, A; Tan, P; Walker, P; Wei, A1
Dell'Aringa, J; Frankel, SR; Gudgeon, CJ; Harrington, KH; Kischel, R; Laszlo, GS; Means, GD; Newhall, KJ; Sinclair, AM; Walter, RB1
Dear, AE; Liu, HB; Spencer, A; Tan, P; Urbanavicius, D1
Deutsch, J; Frees, M; Laux, D; Leon-Ferre, R; Milhem, M; Smith, BJ; Xia, C1
Mascarenhas, J1
Byers, BL; Heninger, E; Jarrard, DF; Kircher, MR; Kosoff, D; Krueger, TE; Lang, JM; McNeel, DG; Sperger, JM; Thiede, SM; Yang, B1
Barwe, SP; Gopalakrishnapillai, A; Quagliano, A1
Arend, RC; Buchsbaum, DJ; Forero, A; Katre, A; Londoño, A; Meza-Perez, S; Norian, LA; Peabody, JE; Randall, TD; Smith, HJ; Straughn, JM; Turner, TB1
Barwe, SP; Gopalakrishnapillai, A; Kolb, EA; McCahan, SM1
Acharyya, S; Borbenyi, Z; Breccia, M; Cavenagh, JD; DeAngelo, DJ; Egyed, M; Fenaux, P; Garcia-Manero, G; Gazi, L; Graux, C; Ide, S; Illes, A; Lee, JH; MacWhannell, A; Marker, M; Ottmann, OG; Salman, H; Sekeres, MA; Stauder, R; Valcarcel, D; Yee, K; Zhu, N1
Kobayashi, T; Kobayashi, Y; Matsuoka, F; Minami, H; Munakata, W; Ogura, M; Shimada, F; Tajima, T; Taniwaki, M; Uchida, T; Yakushijin, K; Yonemura, M1

Reviews

2 review(s) available for azacitidine and panobinostat

ArticleYear
HIV latency reversal agents: A potential path for functional cure?
    European journal of medicinal chemistry, 2021, Mar-05, Volume: 213

    Topics: Anti-HIV Agents; CD4-Positive T-Lymphocytes; Histone Deacetylase Inhibitors; HIV Infections; HIV-1; Humans; Molecular Structure; Virus Latency

2021
Rationale for combination therapy in myelofibrosis.
    Best practice & research. Clinical haematology, 2014, Volume: 27, Issue:2

    Topics: Antimetabolites, Antineoplastic; Azacitidine; Biphenyl Compounds; Clinical Trials as Topic; Decitabine; Drug Therapy, Combination; Gene Expression; Hematopoietic Stem Cells; Homeodomain Proteins; Humans; Hydroxamic Acids; Indoles; Janus Kinase 2; Mutation; Nitriles; Panobinostat; Primary Myelofibrosis; Protein Kinase Inhibitors; Pyrazoles; Pyridines; Pyrimidines; Recombinant Proteins; Serum Amyloid P-Component

2014

Trials

4 trial(s) available for azacitidine and panobinostat

ArticleYear
Reducing TNF receptor 2+ regulatory T cells via the combined action of azacitidine and the HDAC inhibitor, panobinostat for clinical benefit in acute myeloid leukemia patients.
    Clinical cancer research : an official journal of the American Association for Cancer Research, 2014, Feb-01, Volume: 20, Issue:3

    Topics: Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Flow Cytometry; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Panobinostat; Receptors, Tumor Necrosis Factor, Type II; T-Lymphocyte Subsets; T-Lymphocytes, Regulatory

2014
Treatment of resistant metastatic melanoma using sequential epigenetic therapy (decitabine and panobinostat) combined with chemotherapy (temozolomide).
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Antineoplastic Agents, Alkylating; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Dacarbazine; Decitabine; DNA Modification Methylases; Dose-Response Relationship, Drug; Drug Monitoring; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Epigenomics; Eye Neoplasms; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Male; Maximum Tolerated Dose; Melanoma; Middle Aged; Panobinostat; Skin Neoplasms; Temozolomide; Treatment Outcome

2014
A phase 1b/2b multicenter study of oral panobinostat plus azacitidine in adults with MDS, CMML or AML with ⩽30% blasts.
    Leukemia, 2017, Volume: 31, Issue:12

    Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Bone Marrow; Female; Humans; Hydroxamic Acids; Indoles; Kaplan-Meier Estimate; Leukemia, Myeloid, Acute; Leukemia, Myelomonocytic, Chronic; Male; Maximum Tolerated Dose; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome

2017
Phase I study of panobinostat and 5-azacitidine in Japanese patients with myelodysplastic syndrome or chronic myelomonocytic leukemia.
    International journal of hematology, 2018, Volume: 107, Issue:1

    Topics: Aged; Asian People; Azacitidine; Drug Administration Schedule; Drug Therapy, Combination; Female; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Leukemia, Myelomonocytic, Chronic; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome

2018

Other Studies

13 other study(ies) available for azacitidine and panobinostat

ArticleYear
Molecular and biologic characterization and drug sensitivity of pan-histone deacetylase inhibitor-resistant acute myeloid leukemia cells.
    Blood, 2008, Oct-01, Volume: 112, Issue:7

    Topics: Acetylation; Animals; Antineoplastic Agents; Apoptosis; Azacitidine; Benzoquinones; Cell Differentiation; Cell Proliferation; Decitabine; DNA-Binding Proteins; Drug Resistance, Neoplasm; Enzyme Inhibitors; Heat Shock Transcription Factors; Histone Deacetylase Inhibitors; HL-60 Cells; HSP70 Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Humans; Hydroxamic Acids; Indoles; Lactams, Macrocyclic; Leukemia, Myeloid, Acute; Mice; Mice, Inbred NOD; Neoplasm Proteins; Panobinostat; S Phase; Transcription Factors; Tubulin; Vorinostat

2008
Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
    Cancer biology & therapy, 2009, Volume: 8, Issue:10

    Topics: Azacitidine; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA-Binding Proteins; Drug Combinations; Enhancer of Zeste Homolog 2 Protein; Enzyme Inhibitors; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; K562 Cells; Leukemia, Myeloid, Acute; Panobinostat; Polycomb Repressive Complex 2; Promoter Regions, Genetic; Repressor Proteins; Transcription Factors

2009
Combinations of DNA methyltransferase and histone deacetylase inhibitors induce DNA damage in small cell lung cancer cells: correlation of resistance with IFN-stimulated gene expression.
    Molecular cancer therapeutics, 2010, Volume: 9, Issue:8

    Topics: Apoptosis; Azacitidine; Benzamides; Cell Cycle; Cell Line, Tumor; Cell Survival; Decitabine; DNA (Cytosine-5-)-Methyltransferase 1; DNA (Cytosine-5-)-Methyltransferases; DNA Damage; DNA Methylation; Drug Resistance, Neoplasm; Drug Synergism; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Interferons; Lung Neoplasms; Panobinostat; Phosphorylation; Pyrimidines; Small Cell Lung Carcinoma

2010
HDAC inhibitors and decitabine are highly synergistic and associated with unique gene-expression and epigenetic profiles in models of DLBCL.
    Blood, 2011, Nov-17, Volume: 118, Issue:20

    Topics: Acetylation; Animals; Antimetabolites, Antineoplastic; Apoptosis; Azacitidine; Cell Line, Tumor; Decitabine; DNA Methylation; Drug Synergism; Epigenesis, Genetic; Gene Expression Regulation, Neoplastic; Histone Deacetylase Inhibitors; Histones; Humans; Hydroxamic Acids; Indoles; Lymphoma, Large B-Cell, Diffuse; Mice; Mice, SCID; Panobinostat; Xenograft Model Antitumor Assays

2011
ING1 and 5-azacytidine act synergistically to block breast cancer cell growth.
    PloS one, 2012, Volume: 7, Issue:8

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxamic Acids; Indoles; Inhibitor of Growth Protein 1; Intracellular Signaling Peptides and Proteins; Mice; Mice, SCID; Nuclear Proteins; Panobinostat; Tumor Suppressor Proteins; Xenograft Model Antitumor Assays

2012
Quantitative comparison of the efficacy of various compounds in lowering intracellular cholesterol levels in Niemann-Pick type C fibroblasts.
    PloS one, 2012, Volume: 7, Issue:10

    Topics: Azacitidine; beta-Cyclodextrins; Cells, Cultured; Child; Child, Preschool; Chloroquine; Chlorpromazine; Cholesterol; Decitabine; Dose-Response Relationship, Drug; Drug Synergism; Female; Fibroblasts; Humans; Hydroxamic Acids; Indoles; Intracellular Space; Male; Microscopy, Fluorescence; Mutation; Niemann-Pick Disease, Type C; Panobinostat; Sirolimus; Vorinostat

2012
Preclinical screening of histone deacetylase inhibitors combined with ABT-737, rhTRAIL/MD5-1 or 5-azacytidine using syngeneic Vk*MYC multiple myeloma.
    Cell death & disease, 2013, Sep-12, Volume: 4

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Biphenyl Compounds; Drug Screening Assays, Antitumor; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Mice, Inbred C57BL; Mice, Transgenic; Multiple Myeloma; Nitrophenols; Panobinostat; Piperazines; Proto-Oncogene Proteins c-bcl-2; Proto-Oncogene Proteins c-myc; Receptors, Death Domain; Recombinant Proteins; Sulfonamides; TNF-Related Apoptosis-Inducing Ligand

2013
Cellular determinants for preclinical activity of a novel CD33/CD3 bispecific T-cell engager (BiTE) antibody, AMG 330, against human AML.
    Blood, 2014, Jan-23, Volume: 123, Issue:4

    Topics: AC133 Antigen; Antibodies; Antibodies, Bispecific; Antigens, CD; Azacitidine; CD3 Complex; Cell Line, Tumor; Enzyme Inhibitors; Epigenesis, Genetic; Gene Expression Regulation, Leukemic; Glycoproteins; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Leukocytes, Mononuclear; O(6)-Methylguanine-DNA Methyltransferase; Panobinostat; Peptides; Polymorphism, Single Nucleotide; Sialic Acid Binding Ig-like Lectin 3; T-Lymphocytes

2014
Mechanisms and potential molecular markers of early response to combination epigenetic therapy in patients with myeloid malignancies.
    International journal of oncology, 2014, Volume: 45, Issue:4

    Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Cell Proliferation; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Epigenesis, Genetic; Female; Gene Expression Regulation, Leukemic; HL-60 Cells; Humans; Hydroxamic Acids; Indoles; Leukemia, Myeloid, Acute; Male; Middle Aged; Myelodysplastic Syndromes; Panobinostat; Treatment Outcome

2014
Inducible expression of cancer-testis antigens in human prostate cancer.
    Oncotarget, 2016, Dec-20, Volume: 7, Issue:51

    Topics: Antigens, Neoplasm; Antineoplastic Agents; Azacitidine; Biomarkers, Tumor; Cell Line, Tumor; Decitabine; Gene Expression Regulation, Neoplastic; Humans; Hydroxamic Acids; Indoles; Male; Membrane Proteins; Neoplasm Proteins; Neoplastic Cells, Circulating; Panobinostat; Prostatic Neoplasms; Repressor Proteins; Testis

2016
Epigenetic drug combination overcomes osteoblast-induced chemoprotection in pediatric acute lymphoid leukemia.
    Leukemia research, 2017, Volume: 56

    Topics: Animals; Azacitidine; Coculture Techniques; DNA Modification Methylases; Drug Resistance, Neoplasm; Epigenesis, Genetic; Heterografts; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Osteoblasts; Panobinostat; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Tumor Cells, Cultured

2017
Epigenetic modifiers upregulate MHC II and impede ovarian cancer tumor growth.
    Oncotarget, 2017, Jul-04, Volume: 8, Issue:27

    Topics: Animals; Antimetabolites, Antineoplastic; Azacitidine; Benzamides; Cell Line, Tumor; Disease Models, Animal; DNA Methylation; Dose-Response Relationship, Drug; Drug Synergism; Epigenesis, Genetic; Female; Gene Expression Regulation, Neoplastic; Histocompatibility Antigens Class II; Histone Deacetylase Inhibitors; Humans; Hydroxamic Acids; Indoles; Mice; Ovarian Neoplasms; Panobinostat; Pyridines; RNA, Messenger; Transcription, Genetic; Tumor Burden; Xenograft Model Antitumor Assays

2017
Epigenetic drug combination induces remission in mouse xenograft models of pediatric acute myeloid leukemia.
    Leukemia research, 2017, Volume: 58

    Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Azacitidine; Cell Line, Tumor; Child; Drug Synergism; Epigenesis, Genetic; Flow Cytometry; Gene Expression Profiling; Humans; Hydroxamic Acids; Immunoblotting; Indoles; Inhibitory Concentration 50; Leukemia, Myeloid, Acute; Mice; Oligonucleotide Array Sequence Analysis; Panobinostat; Remission Induction; Tumor Suppressor Protein p53; Xenograft Model Antitumor Assays

2017